PolyPid Ltd PYPD
News
European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀
PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities
PolyPid Announces Participation in Upcoming Fall Investor Conferences
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀
PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
